Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Transcriptional misregulation in cancer (mmu05202)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
AK040987
KLA  ATP  ATP+KLA
 AK040987 adult male aorta and vein cDNA, RIKEN full-length enriched library, clone:A530055P18 product:unclassifiable, full insert sequence [AK040987] KLA 1.01 1.01 .99 1.01 .98 1.06 .92
ATP 1.04 .92 1.05 .99 .98 1.00 1.01
KLA/ATP 1.04 1.04 1.03 .98 .98 1.03 1.07
AK047964
KLA  ATP  ATP+KLA
 AK047964 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130024N02 product:unclassifiable, full insert sequence. [AK047964] KLA 1.04 .94 .97 .94 1.00 1.02 .98
ATP .98 .98 1.00 .96 .92 1.11 1.01
KLA/ATP 1.00 .98 1.01 .98 .91 .92 1.00
AK083781
KLA  ATP  ATP+KLA
 AK083781 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130007L03 product:unclassifiable, full insert sequence. [AK083781] KLA .97 1.00 1.07 .97 .99 .95 1.03
ATP 1.04 1.04 1.01 .99 .95 .97 1.08
KLA/ATP .96 1.04 1.02 .97 1.00 1.07 1.02
Aff1
KLA  ATP  ATP+KLA
 NM_133919 AF4/FMR2 family, member 1 (Aff1), transcript variant 2, mRNA [NM_133919] KLA 5.76 5.42 5.73 5.11 3.88 2.98 1.40
ATP .93 .92 1.32 1.32 2.02 4.28 2.03
KLA/ATP 4.79 5.47 6.13 5.06 5.15 4.72 4.02
Arnt2
KLA  ATP  ATP+KLA
 NM_007488 aryl hydrocarbon receptor nuclear translocator 2 (Arnt2), mRNA [NM_007488] KLA 1.06 1.02 1.01 1.02 1.02 1.02 .97
ATP 1.00 1.00 1.03 1.05 .96 1.05 1.23
KLA/ATP .99 .97 .99 .99 1.05 1.08 1.29
Aspscr1
KLA  ATP  ATP+KLA
 NM_026877 alveolar soft part sarcoma chromosome region, candidate 1 (human) (Aspscr1), transcript variant 1, mRNA [NM_026877] KLA .92 .96 .87 .77 .90 1.28 1.32
ATP 1.10 1.26 .84 1.32 .76 .76 1.15
KLA/ATP 1.13 1.02 .56 1.07 .54 .82 1.52
Atf1
KLA  ATP  ATP+KLA
 NM_007497 activating transcription factor 1 (Atf1), mRNA [NM_007497] KLA .71 .73 .74 .79 .89 1.02 1.27
ATP 1.05 1.14 1.17 1.58 4.22 2.94 1.86
KLA/ATP .75 .78 .77 .90 2.98 3.50 2.39
Atm
KLA  ATP  ATP+KLA
 NM_007499 ataxia telangiectasia mutated homolog (human) (Atm), mRNA [NM_007499] KLA 1.86 1.97 2.17 1.67 1.20 .86 .79
ATP 1.09 1.17 1.01 .97 .61 .63 .69
KLA/ATP 2.11 2.24 1.55 1.46 .85 .75 .59
Baiap3
KLA  ATP  ATP+KLA
 AK122358 mRNA for mKIAA0734 protein [AK122358] KLA .95 .98 .92 1.01 1.00 1.09 1.03
ATP 1.03 1.01 .99 1.04 1.02 1.01 .95
KLA/ATP .99 .96 .94 .98 .99 1.15 1.07
Bcl2a1b
KLA  ATP  ATP+KLA
 NM_007534 B-cell leukemia/lymphoma 2 related protein A1b (Bcl2a1b), mRNA [NM_007534] KLA 34.11 34.56 37.57 36.91 28.13 17.63 10.35
ATP 1.02 1.06 1.87 3.05 8.81 14.40 6.63
KLA/ATP 34.55 35.44 49.51 38.70 36.65 17.92 12.39
Bcl2a1c
KLA  ATP  ATP+KLA
 NM_007535 B-cell leukemia/lymphoma 2 related protein A1c (Bcl2a1c), mRNA [NM_007535] KLA 33.96 35.89 36.34 38.52 29.20 19.48 11.43
ATP 1.01 1.08 1.84 2.98 8.29 13.22 6.74
KLA/ATP 30.56 34.60 50.13 43.72 35.49 19.36 15.41
Bcl2l1
KLA  ATP  ATP+KLA
 NM_009743 Bcl2-like 1 (Bcl2l1), nuclear gene encoding mitochondrial protein, mRNA [NM_009743] KLA .99 1.02 1.10 1.16 1.27 .97 1.05
ATP 1.18 1.42 .81 1.26 1.51 .71 1.67
KLA/ATP 1.21 1.30 .66 1.15 1.31 1.17 1.59
Bcl6
KLA  ATP  ATP+KLA
 NM_009744 B-cell leukemia/lymphoma 6 (Bcl6), mRNA [NM_009744] KLA 2.04 1.52 2.00 1.93 1.34 1.49 1.27
ATP 1.03 1.01 2.24 2.40 1.28 .70 .94
KLA/ATP 2.02 1.56 4.43 4.06 3.69 .92 2.00
Birc3
KLA  ATP  ATP+KLA
 BC011338 baculoviral IAP repeat-containing 3, mRNA (cDNA clone MGC:18386 IMAGE:3661563), complete cds [BC011338] KLA 5.48 5.46 4.94 4.16 4.91 3.36 3.74
ATP 1.05 1.08 4.21 4.28 2.59 2.55 1.57
KLA/ATP 6.78 8.91 11.01 4.87 2.28 2.12 3.66
Birc3
KLA  ATP  ATP+KLA
 NM_007464 baculoviral IAP repeat-containing 3 (Birc3), mRNA [NM_007464] KLA 17.83 15.88 13.48 11.14 11.79 6.90 6.10
ATP 1.14 1.16 1.70 4.07 5.00 6.33 2.41
KLA/ATP 14.77 16.44 19.09 13.91 8.27 6.22 7.73
Bmi1
KLA  ATP  ATP+KLA
 NM_007552 Bmi1 polycomb ring finger oncogene (Bmi1), mRNA [NM_007552] KLA 1.28 1.38 1.42 1.42 1.36 1.26 2.24
ATP 1.00 1.09 1.24 1.13 .84 .88 1.47
KLA/ATP 1.39 1.42 1.33 1.27 1.06 1.00 1.49
Bmp2k
KLA  ATP  ATP+KLA
 NM_080708 BMP2 inducible kinase (Bmp2k), mRNA [NM_080708] KLA 1.03 1.04 1.20 1.32 1.84 1.47 1.02
ATP 1.05 1.24 1.25 1.44 1.04 .74 .85
KLA/ATP 1.06 1.11 1.15 1.41 1.09 .91 1.01
CJ309851
KLA  ATP  ATP+KLA
 CJ309851 gb|CJ309851 RIKEN full-length enriched mouse cDNA library, Rathkes pouches 14.5 days embryo Mus musculus cDNA clone M130040E04 3, mRNA sequence [CJ309851] KLA 1.48 1.29 1.14 .93 1.41 1.25 1.07
ATP .90 .75 .59 .35 1.15 1.10 .95
KLA/ATP 1.19 .82 .72 .46 1.13 .90 1.14
CO802710
KLA  ATP  ATP+KLA
 CO802710 gb|AGENCOURT_30288440 NIH_MGC_257 Mus musculus cDNA clone IMAGE:30930506 5, mRNA sequence [CO802710] KLA .87 .99 1.11 1.20 1.68 1.37 .90
ATP .95 .97 1.07 1.11 .95 .94 .71
KLA/ATP .91 .98 1.01 1.15 1.06 .79 .77
Ccna1
KLA  ATP  ATP+KLA
 NM_007628 cyclin A1 (Ccna1), mRNA [NM_007628] KLA .97 .96 1.03 1.01 .97 .96 1.02
ATP .98 .99 1.00 1.01 .98 .95 .98
KLA/ATP 1.05 .96 1.01 1.04 .97 .92 1.01
Ccnd2
KLA  ATP  ATP+KLA
 NM_009829 cyclin D2 (Ccnd2), mRNA [NM_009829] KLA 12.92 13.66 11.94 12.37 11.11 5.44 1.53
ATP .98 .75 .50 .57 1.24 2.83 .40
KLA/ATP 11.19 11.62 10.34 7.96 7.92 7.10 2.57
Ccnt1
KLA  ATP  ATP+KLA
 AK083037 12 days embryo spinal cord cDNA, RIKEN full-length enriched library, clone:C530036C11 product:cyclin T1, full insert sequence. [AK083037] KLA .89 .76 .82 .96 1.15 .91 1.03
ATP 1.12 .93 .79 .96 1.83 1.19 1.00
KLA/ATP .84 .82 .82 .85 1.40 1.13 .95
Ccnt1
KLA  ATP  ATP+KLA
 NM_009833 cyclin T1 (Ccnt1), mRNA [NM_009833] KLA .91 .90 .92 .86 1.22 1.16 1.52
ATP 1.11 1.42 .84 1.56 2.38 1.93 1.58
KLA/ATP 1.11 1.09 .56 1.20 1.47 2.15 2.19
Ccnt2
KLA  ATP  ATP+KLA
 AK156231 activated spleen cDNA, RIKEN full-length enriched library, clone:F830012O13 product:cyclin T2, full insert sequence [AK156231] KLA 1.55 1.40 1.69 1.44 1.50 1.42 1.25
ATP 1.15 1.04 .81 .50 .87 .92 1.06
KLA/ATP 1.65 1.54 1.11 .62 .84 .81 .94
Ccnt2
KLA  ATP  ATP+KLA
 NM_028399 cyclin T2 (Ccnt2), mRNA [NM_028399] KLA 1.73 1.52 1.78 1.52 1.62 1.62 1.50
ATP 1.17 1.08 1.04 .91 1.76 1.62 1.66
KLA/ATP 1.83 1.89 1.43 1.21 1.36 2.09 2.57
Ccr7
KLA  ATP  ATP+KLA
 NM_007719 chemokine (C-C motif) receptor 7 (Ccr7), mRNA [NM_007719] KLA 1.58 1.73 2.00 1.95 2.02 1.77 1.60
ATP 1.07 1.06 1.21 2.11 2.85 2.72 1.78
KLA/ATP 1.76 1.95 3.23 4.65 5.17 5.76 4.07
Cd14
KLA  ATP  ATP+KLA
 NM_009841 CD14 antigen (Cd14), mRNA [NM_009841] KLA 2.35 2.68 2.54 2.21 2.39 1.52 1.57
ATP 1.44 2.28 2.82 3.98 6.68 16.14 6.92
KLA/ATP 2.92 3.79 3.96 5.12 5.29 10.42 11.50
Cd40
KLA  ATP  ATP+KLA
 NM_170701 CD40 antigen (Cd40), transcript variant 3, mRNA [NM_170701] KLA 23.87 23.62 23.26 23.98 22.07 17.37 5.34
ATP 1.00 1.01 1.06 2.96 2.65 3.03 1.70
KLA/ATP 22.77 23.79 29.67 28.85 28.08 21.62 13.02
Cd86
KLA  ATP  ATP+KLA
 NM_019388 CD86 antigen (Cd86), mRNA [NM_019388] KLA 13.80 14.41 18.21 18.33 17.37 17.26 4.82
ATP 1.02 1.00 2.20 3.64 5.16 6.79 3.81
KLA/ATP 14.80 14.66 18.10 18.96 19.38 20.42 14.21
Cdk9
KLA  ATP  ATP+KLA
 NM_130860 cyclin-dependent kinase 9 (CDC2-related kinase) (Cdk9), mRNA [NM_130860] KLA .57 .53 .59 .69 .78 .84 .89
ATP .90 .88 .87 .80 1.03 1.10 1.21
KLA/ATP .50 .50 .58 .79 1.21 1.21 1.11
Cdkn1a
KLA  ATP  ATP+KLA
 NM_007669 cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a), transcript variant 1, mRNA [NM_007669] KLA 4.72 4.90 4.96 3.73 2.11 1.14 1.02
ATP 1.14 1.52 .95 1.69 1.47 2.21 .50
KLA/ATP 5.99 7.08 3.86 6.37 3.00 2.55 2.05
Cdkn1b
KLA  ATP  ATP+KLA
 NM_009875 cyclin-dependent kinase inhibitor 1B (Cdkn1b), mRNA [NM_009875] KLA .81 .84 .84 .91 .93 .88 .97
ATP .99 1.09 .97 1.06 1.48 .94 .91
KLA/ATP .83 .91 1.04 1.36 1.48 1.06 1.09
Cdkn2c
KLA  ATP  ATP+KLA
 NM_007671 cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) (Cdkn2c), mRNA [NM_007671] KLA .32 .29 .29 .27 .20 .20 .15
ATP .88 .87 .62 .52 .49 .39 .23
KLA/ATP .30 .29 .30 .34 .34 .34 .20
Cdkn2c
KLA  ATP  ATP+KLA
 U19596 Cdk4 and Cdk6 inhibitor p18 protein mRNA, complete cds. [U19596] KLA .32 .32 .30 .27 .21 .20 .15
ATP .91 .90 .57 .52 .49 .40 .22
KLA/ATP .35 .31 .29 .36 .35 .35 .20
Cebpa
KLA  ATP  ATP+KLA
 NM_007678 CCAAT/enhancer binding protein (C/EBP), alpha (Cebpa), mRNA [NM_007678] KLA .17 .18 .15 .16 .17 .33 .37
ATP 1.13 1.26 .92 1.72 1.70 .94 1.32
KLA/ATP .21 .18 .19 .36 .87 .81 .72
Cebpb
KLA  ATP  ATP+KLA
 NM_009883 CCAAT/enhancer binding protein (C/EBP), beta (Cebpb), mRNA [NM_009883] KLA 4.23 5.09 5.13 5.70 7.11 6.62 5.94
ATP 1.52 2.60 4.55 14.19 16.93 10.86 3.06
KLA/ATP 4.97 7.06 8.37 18.16 20.66 8.78 8.37
Cebpb
KLA  ATP  ATP+KLA
 X62600 gb|M.musculus mRNA for C/EBP beta. [X62600] KLA 4.28 4.63 4.35 7.32 6.89 7.11 6.82
ATP 1.41 2.03 5.60 13.16 23.55 15.76 3.02
KLA/ATP 4.35 6.27 11.70 17.46 25.69 11.34 9.42
Csf1r
KLA  ATP  ATP+KLA
 NM_001037859 colony stimulating factor 1 receptor (Csf1r), mRNA [NM_001037859] KLA .76 .81 .88 .67 .74 .78 .90
ATP 1.10 1.22 .88 1.10 .87 .78 1.28
KLA/ATP .97 .87 .63 .83 .51 .66 1.18
Csf2
KLA  ATP  ATP+KLA
 NM_009969 colony stimulating factor 2 (granulocyte-macrophage) (Csf2), mRNA [NM_009969] KLA 1.44 1.53 1.38 1.37 1.15 1.21 1.14
ATP 1.01 1.02 1.85 9.73 2.64 1.90 1.14
KLA/ATP 1.49 1.84 2.14 2.80 1.67 1.36 1.35
Ddit3
KLA  ATP  ATP+KLA
 NM_007837 DNA-damage inducible transcript 3 (Ddit3), mRNA [NM_007837] KLA .61 .59 .70 1.06 1.69 2.77 3.31
ATP .87 .65 .80 1.34 1.88 1.58 4.98
KLA/ATP .58 .51 .67 1.54 4.63 3.78 8.88
Ddx5
KLA  ATP  ATP+KLA
 NM_007840 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 (Ddx5), mRNA [NM_007840] KLA 1.36 1.40 1.22 1.23 1.04 1.00 .90
ATP .94 .83 .80 .72 1.35 1.36 .84
KLA/ATP 1.30 1.19 1.09 .94 2.47 1.47 .81
Defcr3
KLA  ATP  ATP+KLA
 NM_007850 defensin related cryptdin 3 (Defcr3), mRNA [NM_007850] KLA 1.11 1.13 1.14 1.18 1.19 1.22 1.24
ATP 1.05 1.09 1.10 1.24 1.26 1.10 1.09
KLA/ATP 1.18 1.22 1.16 1.25 1.31 1.25 1.49
Dot1l
KLA  ATP  ATP+KLA
 NM_199322 DOT1-like, histone H3 methyltransferase (S. cerevisiae) (Dot1l), mRNA [NM_199322] KLA .84 .87 .84 .87 .97 1.15 1.14
ATP 1.03 1.06 1.29 1.94 1.46 1.05 1.54
KLA/ATP .88 .83 1.07 1.47 1.21 1.32 1.64
Dusp6
KLA  ATP  ATP+KLA
 NM_026268 dual specificity phosphatase 6 (Dusp6), mRNA [NM_026268] KLA .10 .08 .09 .08 .12 .25 .16
ATP 1.03 .73 .90 .43 .08 .40 .46
KLA/ATP .09 .07 .12 .13 .07 .11 .21
EG629860
KLA  ATP  ATP+KLA
 M17953 gb|Mouse Ig rearranged H-chain V-region mRNA VJ1 [M17953] KLA .96 1.05 1.03 1.08 1.08 1.02 .98
ATP .97 .99 1.05 1.10 .95 .94 .91
KLA/ATP .96 .94 .97 1.04 .97 1.01 .89
Ela2
KLA  ATP  ATP+KLA
 NM_015779 elastase 2, neutrophil (Ela2), mRNA [NM_015779] KLA .98 1.01 .91 .96 .94 .93 1.07
ATP 1.06 1.07 .94 1.07 1.00 .93 .96
KLA/ATP 1.16 1.08 .87 1.04 .98 1.01 1.02
Elk4
KLA  ATP  ATP+KLA
 AK037559 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026I01 product:unclassifiable, full insert sequence. [AK037559] KLA 1.04 .93 .96 .94 .99 1.06 .93
ATP .95 .98 .89 .92 .96 1.00 .96
KLA/ATP .94 .94 .99 .92 .93 .99 .96
Elk4
KLA  ATP  ATP+KLA
 NM_007923 ELK4, member of ETS oncogene family (Elk4), mRNA [NM_007923] KLA .96 1.04 1.07 1.04 1.05 1.01 1.09
ATP .93 1.01 1.02 1.01 1.00 1.10 1.01
KLA/ATP .98 1.01 .94 1.02 1.03 1.04 1.04
Erg
KLA  ATP  ATP+KLA
 AK078113 adult male medulla oblongata cDNA, RIKEN full-length enriched library, clone:6330501C04 product:ERG PROTEIN homolog [Mus musculus], full insert sequence [AK078113] KLA 1.09 1.00 1.02 1.02 1.02 .98 .96
ATP 1.06 1.09 1.00 .93 .96 1.06 1.05
KLA/ATP .95 1.02 1.06 .94 1.02 1.03 1.07
Erg
KLA  ATP  ATP+KLA
 NM_133659 avian erythroblastosis virus E-26 (v-ets) oncogene related (Erg), mRNA [NM_133659] KLA .93 1.02 1.04 1.01 .99 .98 1.02
ATP 1.02 1.03 .97 1.01 1.06 1.00 .97
KLA/ATP 1.04 1.02 1.00 .95 1.06 1.00 .98
Etv1
KLA  ATP  ATP+KLA
 NM_007960 ets variant gene 1 (Etv1), mRNA [NM_007960] KLA .41 .37 .51 .65 .62 .70 .71
ATP 1.16 1.10 1.03 1.11 .66 .38 .86
KLA/ATP .46 .41 .68 .74 .45 .33 .43
Etv4
KLA  ATP  ATP+KLA
 NM_008815 ets variant gene 4 (E1A enhancer binding protein, E1AF) (Etv4), mRNA [NM_008815] KLA .99 1.03 1.00 .99 .97 1.07 .97
ATP 1.03 .99 1.19 1.11 1.19 1.38 1.57
KLA/ATP 1.01 1.05 1.02 1.09 1.07 1.25 1.45
Etv5
KLA  ATP  ATP+KLA
 NM_023794 ets variant gene 5 (Etv5), mRNA [NM_023794] KLA .40 .36 .34 .39 .61 .87 .63
ATP 1.12 1.13 1.06 1.18 .60 .41 1.09
KLA/ATP .40 .39 .40 .40 .38 .46 .92
Etv6
KLA  ATP  ATP+KLA
 NM_007961 ets variant gene 6 (TEL oncogene) (Etv6), mRNA [NM_007961] KLA 6.52 6.81 7.26 6.58 5.39 3.34 2.03
ATP .98 1.00 1.01 1.45 2.23 4.97 2.55
KLA/ATP 6.58 6.68 6.84 7.28 4.17 5.81 5.08
Ewsr1
KLA  ATP  ATP+KLA
 NM_007968 Ewing sarcoma breakpoint region 1 (Ewsr1), mRNA [NM_007968] KLA 1.15 1.10 1.15 1.15 1.21 1.25 1.10
ATP 1.14 1.15 1.12 1.25 1.19 1.11 1.61
KLA/ATP 1.20 1.26 1.28 1.46 1.17 1.08 1.79
Eya1
KLA  ATP  ATP+KLA
 NM_010164 eyes absent 1 homolog (Drosophila) (Eya1), mRNA [NM_010164] KLA .23 .19 .22 .23 .19 .24 .31
ATP 1.03 .98 1.27 1.40 3.01 .66 .88
KLA/ATP .22 .20 .27 .64 1.59 .55 .29
Eya1
KLA  ATP  ATP+KLA
 U61110 Eya1 homolog mRNA, complete cds. [U61110] KLA .75 .71 .70 .66 .60 .71 .67
ATP 1.13 1.12 1.06 1.25 1.82 .78 1.02
KLA/ATP .66 .74 .70 .88 .97 .80 .69
Fcgr1
KLA  ATP  ATP+KLA
 AF143181 strain AB/H (Biozzi) high affinity immunoglobulin gamma Fc receptor I (Fcgr1) mRNA, Fcgr1-d allele, complete cds. [AF143181] KLA 4.27 4.21 5.59 6.14 8.13 9.76 10.98
ATP 1.23 1.12 1.08 1.36 1.09 2.09 11.81
KLA/ATP 4.56 4.93 4.95 5.88 6.66 9.64 23.09
Fcgr1
KLA  ATP  ATP+KLA
 NM_010186 Fc receptor, IgG, high affinity I (Fcgr1), mRNA [NM_010186] KLA 4.31 4.37 4.70 5.97 6.59 10.06 8.67
ATP 1.01 .88 1.16 .89 .90 2.15 9.23
KLA/ATP 4.01 4.10 5.52 4.54 6.31 9.24 15.83
Fev
KLA  ATP  ATP+KLA
 NM_153111 FEV (ETS oncogene family) (Fev), mRNA [NM_153111] KLA 1.03 1.12 1.05 1.05 1.04 1.08 .88
ATP .95 1.01 1.07 .99 .98 1.00 1.00
KLA/ATP 1.00 .95 1.05 1.00 1.03 .89 .95
Fli1
KLA  ATP  ATP+KLA
 NM_008026 Friend leukemia integration 1 (Fli1), mRNA [NM_008026] KLA .20 .18 .18 .28 .46 .76 .58
ATP .93 .90 .96 .70 .64 .51 1.00
KLA/ATP .18 .19 .21 .19 .36 .37 .82
Flt1
KLA  ATP  ATP+KLA
 NM_010228 FMS-like tyrosine kinase 1 (Flt1), mRNA [NM_010228] KLA 3.02 2.74 2.92 3.54 3.71 3.82 1.43
ATP .88 .85 1.07 .85 .94 1.31 1.16
KLA/ATP 2.60 2.99 3.08 2.13 2.23 2.00 2.59
Flt3
KLA  ATP  ATP+KLA
 NM_010229 FMS-like tyrosine kinase 3 (Flt3), mRNA [NM_010229] KLA .99 1.01 1.05 1.01 1.05 1.01 1.01
ATP .92 .98 1.09 1.12 1.00 1.02 1.03
KLA/ATP 1.04 .99 .89 1.01 .99 .94 1.05
Foxo1
KLA  ATP  ATP+KLA
 NM_019739 forkhead box O1 (Foxo1), mRNA [NM_019739] KLA .60 .55 .60 .58 .49 .60 .71
ATP .96 1.03 1.08 1.03 2.49 1.70 .98
KLA/ATP .56 .58 .67 .83 1.47 1.57 .97
Fus
KLA  ATP  ATP+KLA
 AK038226 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130088D05 product:fusion, derived from t(12;16) malignant liposarcoma (human), full insert sequence [AK038226] KLA .46 .40 .43 .67 .80 .77 .88
ATP 1.07 .61 .63 .61 1.34 1.36 .98
KLA/ATP .42 .31 .45 .59 1.03 1.12 1.10
Fus
KLA  ATP  ATP+KLA
 NM_139149 fusion, derived from t(12;16) malignant liposarcoma (human) (Fus), mRNA [NM_139149] KLA 1.25 1.32 1.34 1.22 1.18 1.17 .79
ATP 1.06 1.26 .98 1.27 1.03 1.03 1.20
KLA/ATP 1.28 1.76 1.34 1.58 1.07 .99 1.13
Fut8
KLA  ATP  ATP+KLA
 NM_016893 fucosyltransferase 8 (Fut8), mRNA [NM_016893] KLA 1.94 2.07 2.76 2.41 2.70 1.87 1.31
ATP 1.04 1.15 1.04 1.06 .69 .88 1.12
KLA/ATP 1.99 2.22 1.76 2.02 1.28 1.78 1.60
Golph3
KLA  ATP  ATP+KLA
 BC031445 golgi phosphoprotein 3, mRNA (cDNA clone MGC:25472 IMAGE:4482612), complete cds [BC031445] KLA 1.53 1.68 1.58 1.56 1.43 1.46 1.52
ATP .96 1.07 1.02 1.41 1.20 1.62 1.40
KLA/ATP 1.47 1.43 1.24 1.63 1.18 1.77 2.28
Golph3
KLA  ATP  ATP+KLA
 NM_025673 golgi phosphoprotein 3 (Golph3), mRNA [NM_025673] KLA 1.49 1.53 1.64 1.26 1.42 1.23 1.16
ATP 1.16 1.45 1.05 1.46 1.32 1.37 1.42
KLA/ATP 1.62 1.67 1.03 1.83 1.11 1.68 2.20
Golph3l
KLA  ATP  ATP+KLA
 AK089547 B6-derived CD11 +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F730116A10 product:unclassifiable, full insert sequence. [AK089547] KLA 1.02 .98 .93 1.02 1.04 1.05 1.02
ATP .96 .97 .96 .98 .99 1.00 1.00
KLA/ATP 1.08 .92 .83 1.02 .92 1.05 1.09
Golph3l
KLA  ATP  ATP+KLA
 NM_146133 golgi phosphoprotein 3-like (Golph3l), mRNA [NM_146133] KLA .78 .73 .77 .96 1.20 1.38 1.22
ATP 1.03 1.08 .96 .77 1.07 1.44 1.94
KLA/ATP .70 .74 .74 .65 1.15 2.15 3.15
Gria3
KLA  ATP  ATP+KLA
 AK161163 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4831401I16 product:glutamate receptor, ionotropic, AMPA3 (alpha 3), full insert sequence. [AK161163] KLA 1.01 .96 .97 .95 .99 .84 .81
ATP 1.05 1.04 1.07 .86 .88 .84 .65
KLA/ATP .94 .95 1.06 .83 .79 .75 .66
Gria3
KLA  ATP  ATP+KLA
 NM_016886 glutamate receptor, ionotropic, AMPA3 (alpha 3) (Gria3), mRNA [NM_016886] KLA 1.04 .95 1.05 .98 .98 .97 .95
ATP 1.00 1.08 1.01 .97 .93 .98 .97
KLA/ATP 1.03 .93 .93 .98 .96 1.03 .89
Gzmb
KLA  ATP  ATP+KLA
 NM_013542 granzyme B (Gzmb), mRNA [NM_013542] KLA 1.03 .96 1.07 1.10 1.04 .98 1.07
ATP .90 1.05 1.02 .98 .90 1.09 1.02
KLA/ATP .96 .98 1.20 1.17 1.03 1.06 1.07
H3f3a
KLA  ATP  ATP+KLA
 NM_008210 H3 histone, family 3A (H3f3a), mRNA [NM_008210] KLA 1.06 1.08 1.16 1.19 1.21 1.49 1.57
ATP .99 .99 1.28 1.21 1.52 1.81 .78
KLA/ATP .91 .92 1.42 1.41 1.97 2.07 1.27
H3f3b
KLA  ATP  ATP+KLA
 NM_008211 H3 histone, family 3B (H3f3b), mRNA [NM_008211] KLA 2.30 2.24 2.39 2.46 2.24 2.79 1.50
ATP .85 .87 2.00 2.47 1.89 1.71 .93
KLA/ATP 2.10 2.17 3.76 4.47 4.37 3.19 2.20
Hdac1
KLA  ATP  ATP+KLA
 U80780 putative histone deacetylase (HD1) mRNA, partial cds [U80780] KLA 2.59 2.39 2.48 2.74 3.36 2.56 1.22
ATP 1.13 1.26 1.18 1.08 .85 1.29 1.15
KLA/ATP 2.15 2.27 2.64 2.57 1.78 1.89 2.31
Hdac2
KLA  ATP  ATP+KLA
 AK051753 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130072G11 product:histone deacetylase 2, full insert sequence [AK051753] KLA .97 .97 .90 .96 1.02 .93 .96
ATP 1.02 1.03 .98 .96 .96 .90 1.05
KLA/ATP 1.00 .96 .87 .99 .92 1.00 .95
Hdac2
KLA  ATP  ATP+KLA
 NM_008229 histone deacetylase 2 (Hdac2), mRNA [NM_008229] KLA 1.27 1.35 1.33 1.18 1.03 .75 1.10
ATP .95 1.05 .79 .96 .82 .85 .81
KLA/ATP 1.28 1.43 .93 1.10 .82 .73 .60
Hhex
KLA  ATP  ATP+KLA
 NM_008245 hematopoietically expressed homeobox (Hhex), mRNA [NM_008245] KLA 1.79 1.67 1.40 .64 .47 1.02 .64
ATP .97 1.04 1.01 .74 .34 .36 .60
KLA/ATP 1.63 1.58 1.79 1.12 .49 .44 .34
Hist1h3a
KLA  ATP  ATP+KLA
 NM_013550 histone cluster 1, H3a (Hist1h3a), mRNA [NM_013550] KLA .86 .91 1.03 1.06 .96 .97 .95
ATP .97 1.14 2.05 3.06 2.48 2.55 1.19
KLA/ATP .92 1.04 1.38 1.85 1.82 1.79 1.27
Hist1h3d
KLA  ATP  ATP+KLA
 NM_178204 histone cluster 1, H3d (Hist1h3d), mRNA [NM_178204] KLA 2.02 2.07 2.29 2.29 2.12 2.54 1.63
ATP 1.00 .98 1.54 2.39 2.20 2.14 1.36
KLA/ATP 2.02 2.20 3.05 4.09 4.58 3.59 3.12
Hist2h3c
1
KLA  ATP  ATP+KLA
 NM_178216 histone cluster 2, H3c1 (Hist2h3c1), transcript variant 2, mRNA [NM_178216] KLA 1.98 2.04 2.22 2.28 2.10 2.55 1.66
ATP .95 .90 1.44 2.09 1.84 2.00 1.40
KLA/ATP 1.94 1.90 3.07 3.84 4.33 3.44 3.00
Hmga2
KLA  ATP  ATP+KLA
 AK035164 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430095D03 product:unclassifiable, full insert sequence. [AK035164] KLA .43 .41 .29 .39 .42 .40 .61
ATP 1.24 1.54 1.00 .95 .69 .44 1.22
KLA/ATP .47 .44 .37 .44 .56 .42 .77
Hmga2
KLA  ATP  ATP+KLA
 NM_010441 high mobility group AT-hook 2 (Hmga2), mRNA [NM_010441] KLA .71 .63 .53 .45 .25 .12 .14
ATP 1.04 1.19 .99 1.00 .90 .30 1.10
KLA/ATP .72 .67 .53 .54 .33 .18 .36
Hoxa10
KLA  ATP  ATP+KLA
 NM_008263 homeo box A10 (Hoxa10), transcript variant 1, mRNA [NM_008263] KLA 1.04 1.04 1.05 1.02 .99 .94 .99
ATP .95 .95 .90 .97 .99 1.04 1.03
KLA/ATP .99 .99 .98 1.01 1.05 .97 .95
Hoxa11
KLA  ATP  ATP+KLA
 NM_010450 homeo box A11 (Hoxa11), mRNA [NM_010450] KLA 1.02 1.02 1.02 1.04 1.03 1.06 .95
ATP 1.04 1.06 .96 1.04 .98 1.01 1.02
KLA/ATP 1.03 1.01 .99 .95 1.04 .98 1.00
Hoxa9
KLA  ATP  ATP+KLA
 NM_010456 homeo box A9 (Hoxa9), mRNA [NM_010456] KLA .95 1.02 1.06 1.07 1.02 1.07 1.05
ATP 1.03 1.02 1.02 .98 1.05 1.06 1.02
KLA/ATP 1.05 1.05 1.01 1.03 1.10 1.06 1.07
Hpgd
KLA  ATP  ATP+KLA
 NM_008278 hydroxyprostaglandin dehydrogenase 15 (NAD) (Hpgd), mRNA [NM_008278] KLA .67 .66 .71 .71 .56 .44 .25
ATP 1.04 1.11 1.25 1.14 .81 .46 .28
KLA/ATP .68 .69 .88 .88 .73 .56 .28
Id2
KLA  ATP  ATP+KLA
 NM_010496 inhibitor of DNA binding 2 (Id2), mRNA [NM_010496] KLA .91 1.00 1.04 1.09 1.46 1.70 1.98
ATP 1.17 1.43 3.42 12.70 9.83 2.42 4.02
KLA/ATP 1.07 1.16 1.76 7.26 7.29 1.58 4.38
Igf1
KLA  ATP  ATP+KLA
 AK050118 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730016P09 product:unclassifiable, full insert sequence. [AK050118] KLA .13 .14 .15 .16 .22 .34 .48
ATP 1.78 2.05 1.37 .72 .34 .41 .58
KLA/ATP .24 .45 .50 .24 .20 .26 .68
Igf1
KLA  ATP  ATP+KLA
 NM_010512 insulin-like growth factor 1 (Igf1), transcript variant 1, mRNA [NM_010512] KLA .84 .78 .76 .67 .54 .48 .59
ATP .97 .98 1.13 1.13 1.03 .88 .89
KLA/ATP .82 .81 .93 .86 .83 .65 .89
Igf1
KLA  ATP  ATP+KLA
 NM_184052 insulin-like growth factor 1 (Igf1), transcript variant 2, mRNA [NM_184052] KLA .77 .82 .76 .65 .60 .52 .69
ATP 1.01 1.07 .98 1.06 1.03 .78 .94
KLA/ATP .89 .86 .77 .80 .75 .65 .89
Igf1r
KLA  ATP  ATP+KLA
 NM_010513 insulin-like growth factor I receptor (Igf1r), mRNA [NM_010513] KLA 1.32 1.32 1.08 .91 .55 .48 .45
ATP 1.03 1.06 1.06 1.29 1.31 1.45 .47
KLA/ATP 1.30 1.37 1.11 1.00 .93 1.02 .45
Igfbp3
KLA  ATP  ATP+KLA
 AK045003 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130018L24 product:unclassifiable, full insert sequence. [AK045003] KLA .92 1.01 .99 .97 .98 .98 1.05
ATP 1.00 .91 1.13 1.00 1.00 1.01 .95
KLA/ATP .99 1.07 1.02 .94 .97 1.03 .98
Igfbp3
KLA  ATP  ATP+KLA
 NM_008343 insulin-like growth factor binding protein 3 (Igfbp3), mRNA [NM_008343] KLA .94 .88 .95 .93 .95 .96 .92
ATP .97 1.04 1.03 1.02 1.06 1.04 .90
KLA/ATP .95 .94 .92 .92 1.01 .96 .94
Igfbp3
KLA  ATP  ATP+KLA
 X81581 gb|M.musculus mRNA for insulin-like growth factor binding protein-3. [X81581] KLA .97 .94 1.00 1.05 .99 1.05 1.01
ATP 1.05 1.06 1.06 1.03 1.04 1.01 1.06
KLA/ATP .99 1.07 1.07 .99 .97 1.09 1.02
Igh-VJ55
8
KLA  ATP  ATP+KLA
 AY547436 immunoglobulin heavy chain VDJ region mRNA, partial cds [AY547436] KLA 1.06 1.05 1.01 .93 1.03 .96 .93
ATP .99 1.00 1.06 .95 .96 1.06 1.05
KLA/ATP .98 .94 1.07 .95 .97 .99 1.02
Igh-VJ55
8
KLA  ATP  ATP+KLA
 CA578712 gb|K0727F04-5N NIA Mouse Hematopoietic Stem Cell (Lin- [CA578712] KLA .99 .94 1.01 1.10 .93 .97 .92
ATP .93 1.04 1.01 .98 1.05 .96 .95
KLA/ATP .99 .95 .95 .98 1.02 .98 .95
Igh-VJ55
8
KLA  ATP  ATP+KLA
 ENSMUST00000103412 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHA] [ENSMUST00000103412] KLA 1.01 .97 1.20 1.01 .98 1.44 1.24
ATP .99 .98 1.07 1.03 1.00 1.01 1.21
KLA/ATP .99 1.02 .96 1.03 .97 1.13 1.30
Igh-VJ55
8
KLA  ATP  ATP+KLA
 ENSMUST00000103413 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHE] [ENSMUST00000103413] KLA 1.00 .99 1.06 1.06 .99 1.03 1.02
ATP 1.08 1.06 1.06 1.06 1.02 1.06 .95
KLA/ATP 1.00 1.04 1.09 1.02 1.06 1.02 .95
Igh-VJ55
8
KLA  ATP  ATP+KLA
 U39781 J558+ IgM heavy chain mRNA, hybridoma clone ME2B7, partial cds. [U39781] KLA .93 .89 .98 .97 1.03 1.00 .94
ATP 1.04 1.02 1.08 .94 .93 .90 .79
KLA/ATP .88 .89 .97 .93 .88 .92 .82
Il1r2
KLA  ATP  ATP+KLA
 NM_010555 interleukin 1 receptor, type II (Il1r2), mRNA [NM_010555] KLA 1.05 1.03 1.08 1.13 1.09 1.08 1.14
ATP 1.03 1.08 1.30 1.68 1.38 1.10 1.19
KLA/ATP 1.08 1.14 1.17 1.27 1.10 1.11 2.03
Il2rb
KLA  ATP  ATP+KLA
 NM_008368 interleukin 2 receptor, beta chain (Il2rb), mRNA [NM_008368] KLA .92 1.00 1.00 1.00 .91 .98 1.09
ATP 1.02 .98 1.00 .95 1.02 1.04 1.04
KLA/ATP 1.03 .98 1.01 .99 .94 1.13 1.00
Il3
KLA  ATP  ATP+KLA
 NM_010556 interleukin 3 (Il3), mRNA [NM_010556] KLA 1.05 .94 1.01 .99 1.03 1.07 .95
ATP .95 1.03 1.03 .98 .98 .97 .96
KLA/ATP 1.02 1.03 1.02 .94 .97 1.02 1.04
Il6
KLA  ATP  ATP+KLA
 NM_031168 interleukin 6 (Il6), mRNA [NM_031168] KLA 352.99 378.70 276.81 168.47 59.99 18.66 8.27
ATP 1.04 1.08 2.28 3.69 30.40 161.93 2.11
KLA/ATP 334.28 528.66 ###.## 935.86 302.45 355.36 99.65
Itgam
KLA  ATP  ATP+KLA
 NM_001082960 integrin alpha M (Itgam), transcript variant 1, mRNA [NM_001082960] KLA 1.04 1.12 1.14 1.07 1.54 1.80 1.72
ATP 1.17 1.19 .97 1.16 .86 .65 1.33
KLA/ATP 1.19 1.19 .94 1.06 .64 .59 1.08
Itgam
KLA  ATP  ATP+KLA
 NM_008401 integrin alpha M (Itgam), transcript variant 2, mRNA [NM_008401] KLA 1.20 1.16 1.21 1.34 1.59 1.79 1.64
ATP 1.15 1.16 .94 1.20 1.00 .78 1.25
KLA/ATP 1.32 1.37 1.29 1.14 .84 .75 1.16
Itgb7
KLA  ATP  ATP+KLA
 NM_013566 integrin beta 7 (Itgb7), mRNA [NM_013566] KLA .91 .88 .93 1.19 .93 .76 .79
ATP 1.00 .96 1.30 1.44 2.84 3.07 7.90
KLA/ATP .96 1.05 1.35 1.20 2.70 3.53 8.17
Jmjd1c
KLA  ATP  ATP+KLA
 XM_975833 gb|PREDICTED: Mus musculus jumonji domain containing 1C (Jmjd1c), mRNA [XM_975833] KLA .43 .42 .43 .45 .49 .64 .84
ATP 1.23 1.45 1.58 2.39 1.15 .45 1.13
KLA/ATP .45 .49 .65 1.15 .71 .47 1.05
Jup
KLA  ATP  ATP+KLA
 NM_010593 junction plakoglobin (Jup), mRNA [NM_010593] KLA .96 .98 .98 .88 .99 1.26 .77
ATP .99 1.08 .99 .99 .98 1.06 .82
KLA/ATP .96 .92 .92 .93 1.00 1.49 .80
Klf3
KLA  ATP  ATP+KLA
 NM_008453 Kruppel-like factor 3 (basic) (Klf3), mRNA [NM_008453] KLA 2.04 2.02 2.03 2.40 2.88 2.18 1.90
ATP 1.04 1.12 .93 .97 1.62 1.43 1.50
KLA/ATP 2.15 2.00 1.69 1.92 1.99 1.46 2.74
Ldb1
KLA  ATP  ATP+KLA
 NM_010697 LIM domain binding 1 (Ldb1), transcript variant 3, mRNA [NM_010697] KLA .55 .56 .56 .66 .83 .93 1.04
ATP 1.09 1.13 .90 1.16 .84 .76 .95
KLA/ATP .64 .62 .56 .62 .69 .76 .93
Lmo2
KLA  ATP  ATP+KLA
 NM_008505 LIM domain only 2 (Lmo2), mRNA [NM_008505] KLA .90 1.01 1.15 1.11 .83 .83 .66
ATP 1.07 1.21 .95 1.22 .94 .42 .81
KLA/ATP 1.02 1.08 .95 1.31 .84 .49 .55
Lyl1
KLA  ATP  ATP+KLA
 NM_008535 lymphoblastomic leukemia (Lyl1), mRNA [NM_008535] KLA .04 .04 .06 .13 .25 .33 .42
ATP .91 .78 .57 .44 .23 .19 .56
KLA/ATP .03 .03 .03 .05 .15 .19 .51
Maf
KLA  ATP  ATP+KLA
 NM_001025577 avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog (Maf), mRNA [NM_001025577] KLA 1.44 1.52 1.87 2.44 2.13 1.67 .69
ATP 1.01 1.07 .75 .90 .43 .67 .94
KLA/ATP 1.37 1.44 1.20 1.47 .86 .77 1.00
Max
KLA  ATP  ATP+KLA
 NM_008558 Max protein (Max), mRNA [NM_008558] KLA 3.40 3.25 4.09 4.53 3.19 2.71 1.19
ATP 1.17 1.09 1.13 .86 1.24 1.40 1.09
KLA/ATP 3.14 3.36 5.49 3.83 4.35 2.96 1.67
Mdm2
KLA  ATP  ATP+KLA
 NM_010786 transformed mouse 3T3 cell double minute 2 (Mdm2), mRNA [NM_010786] KLA 1.77 1.59 1.98 1.51 1.77 1.60 1.77
ATP 1.01 1.21 1.36 3.24 5.04 2.08 1.36
KLA/ATP 1.89 1.86 2.93 5.65 5.98 2.78 2.64
Mef2c
KLA  ATP  ATP+KLA
 AK044643 adult retina cDNA, RIKEN full-length enriched library, clone:A930029G05 product:unclassifiable, full insert sequence. [AK044643] KLA .97 .95 .99 .99 .96 .92 .97
ATP 1.03 1.09 1.08 .96 1.03 .85 .90
KLA/ATP .92 .99 .94 .83 .90 .93 .91
Mef2c
KLA  ATP  ATP+KLA
 NM_025282 myocyte enhancer factor 2C (Mef2c), mRNA [NM_025282] KLA .36 .35 .34 .44 .25 .31 .24
ATP 1.10 .84 .84 .97 .39 .19 .41
KLA/ATP .35 .32 .41 .44 .33 .19 .18
Meis1
KLA  ATP  ATP+KLA
 NM_010789 Meis homeobox 1 (Meis1), mRNA [NM_010789] KLA .90 .87 .82 .87 .79 .76 .82
ATP 1.04 1.11 1.00 .90 .77 .84 .82
KLA/ATP .89 .91 .83 .82 .74 .73 .71
Men1
KLA  ATP  ATP+KLA
 NM_008583 multiple endocrine neoplasia 1 (Men1), mRNA [NM_008583] KLA 1.31 1.38 1.35 1.34 1.32 1.08 1.03
ATP 1.01 1.16 1.03 1.24 .99 1.20 1.02
KLA/ATP 1.55 1.46 1.12 1.41 1.15 1.34 1.14
Met
KLA  ATP  ATP+KLA
 NM_008591 met proto-oncogene (Met), mRNA [NM_008591] KLA 3.56 3.71 3.68 3.79 4.24 5.89 6.95
ATP .98 .96 1.16 1.21 3.32 12.98 6.60
KLA/ATP 3.75 3.80 3.58 3.28 3.69 4.27 14.22
Mlf1
KLA  ATP  ATP+KLA
 NM_010801 myeloid leukemia factor 1 (Mlf1), transcript variant 2, mRNA [NM_010801] KLA .77 .79 .78 .79 .67 .64 .43
ATP .89 1.01 1.17 1.04 .82 .68 .38
KLA/ATP .72 .74 .85 .84 .71 .62 .38
Mll1
KLA  ATP  ATP+KLA
 NM_001081049 myeloid/lymphoid or mixed-lineage leukemia 1 (Mll1), mRNA [NM_001081049] KLA 1.48 1.42 1.39 1.11 1.28 1.10 1.12
ATP 1.08 1.08 1.16 1.22 1.77 1.14 1.00
KLA/ATP 1.59 1.62 1.59 1.37 1.89 1.23 1.28
Mllt1
KLA  ATP  ATP+KLA
 NM_022328 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 1 (Mllt1), mRNA [NM_022328] KLA 1.10 1.10 1.11 1.30 1.38 1.67 1.81
ATP 1.02 1.06 1.16 1.27 1.02 1.49 1.36
KLA/ATP 1.07 1.11 1.22 1.24 1.10 1.22 1.64
Mllt3
KLA  ATP  ATP+KLA
 NM_027326 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 3 (Mllt3), transcript variant 1, mRNA [NM_027326] KLA 3.67 3.99 4.63 5.37 2.56 1.53 1.07
ATP 1.06 1.04 1.25 1.41 3.47 3.18 2.32
KLA/ATP 3.47 3.73 5.61 4.68 5.60 3.71 1.98
Mm.1371
KLA  ATP  ATP+KLA
 142349183 Unknown KLA .97 .97 1.02 1.06 1.00 .96 1.09
ATP .97 .92 .98 1.06 1.06 .98 1.00
KLA/ATP 1.02 1.05 1.39 1.05 1.06 1.04 1.02
Mm.16453
1
KLA  ATP  ATP+KLA
 118130984 Unknown KLA .96 1.04 1.04 1.06 1.02 .99 .92
ATP .96 1.02 1.00 .92 .94 1.00 .96
KLA/ATP .94 .95 1.03 .99 .95 .95 1.00
Mm.21517
3
KLA  ATP  ATP+KLA
 6755215 Unknown KLA 1.07 1.05 1.04 1.01 .97 1.06 .93
ATP 1.03 1.00 1.00 1.11 1.07 1.02 1.04
KLA/ATP .99 1.02 .96 .97 .98 1.04 1.11
Mm.2389
KLA  ATP  ATP+KLA
 124486681 Unknown KLA 1.53 1.23 1.29 1.19 1.25 1.01 .97
ATP 1.13 .98 1.41 .90 1.87 1.09 .91
KLA/ATP 1.63 1.58 2.26 .94 1.95 1.04 1.01
Mm.24957
5
KLA  ATP  ATP+KLA
 118130178 Unknown KLA .99 .99 1.01 1.01 .99 1.02 .95
ATP 1.03 .98 1.02 1.03 1.11 1.05 1.00
KLA/ATP 1.07 1.06 1.02 1.11 1.05 1.11 1.00
Mm.27574
2
KLA  ATP  ATP+KLA
 112983655 Unknown KLA 1.35 1.16 .94 .85 .45 .33 .31
ATP .90 .86 1.17 1.09 1.18 1.21 .38
KLA/ATP 1.12 1.22 1.19 .91 .90 .83 .33
Mm.2932
KLA  ATP  ATP+KLA
 116268120 Unknown KLA 1.74 1.87 2.38 2.24 2.14 1.97 1.66
ATP 1.06 .97 1.25 2.61 3.26 3.23 1.78
KLA/ATP 2.10 2.32 3.52 5.43 5.89 6.74 4.66
Mm.38933
9
KLA  ATP  ATP+KLA
 120444921 Unknown KLA 1.03 1.07 .95 .95 1.07 1.00 .93
ATP .96 .94 1.01 .98 .94 .94 1.03
KLA/ATP .98 .98 .98 .97 .97 1.02 1.05
Mm.42268
0
KLA  ATP  ATP+KLA
 9506766 Unknown KLA 2.08 2.13 2.15 2.32 2.08 2.61 1.60
ATP .92 .92 1.55 2.40 2.08 2.17 1.45
KLA/ATP 1.95 2.02 3.30 4.29 4.84 3.79 3.35
Mm.44011
4
KLA  ATP  ATP+KLA
 134031939 Unknown KLA .99 .98 1.06 1.04 1.00 .98 1.00
ATP 1.07 1.13 .98 .97 1.00 .96 1.01
KLA/ATP 1.02 1.04 1.06 1.02 .96 .96 .92
Mm.47349
7
KLA  ATP  ATP+KLA
 149261268 Unknown KLA .28 .27 .26 .32 .33 .54 .57
ATP .99 .78 1.41 1.41 .84 .37 .84
KLA/ATP .26 .26 .39 .57 .53 .34 .70
Mm.47351
0
KLA  ATP  ATP+KLA
 162287332 Unknown KLA 4.46 4.82 5.29 4.00 2.26 1.25 1.10
ATP 1.24 1.72 1.02 2.08 1.66 2.53 .55
KLA/ATP 6.11 7.67 4.29 6.99 3.11 2.86 2.30
Mm.5025
KLA  ATP  ATP+KLA
 121582413 Unknown KLA 1.12 1.10 1.21 1.22 1.13 1.21 .98
ATP 1.01 1.04 1.11 1.19 1.17 1.09 1.09
KLA/ATP 1.22 1.25 1.41 1.22 1.26 1.12 1.15
Mm.80682
KLA  ATP  ATP+KLA
 94369627 Unknown KLA .96 1.00 .97 .97 1.07 1.05 .99
ATP .97 1.02 .98 1.01 1.01 1.06 .96
KLA/ATP 1.00 .93 1.02 1.08 .98 .95 .97
Mmp3
KLA  ATP  ATP+KLA
 NM_010809 matrix metallopeptidase 3 (Mmp3), mRNA [NM_010809] KLA 1.02 1.04 1.04 1.04 .99 1.04 .97
ATP 1.00 1.01 .99 1.01 1.12 3.52 2.55
KLA/ATP 1.01 1.07 .99 .99 .99 1.11 1.16
Mmp9
KLA  ATP  ATP+KLA
 NM_013599 matrix metallopeptidase 9 (Mmp9), mRNA [NM_013599] KLA 1.49 1.65 1.43 1.32 1.46 1.33 2.10
ATP 1.03 1.05 1.12 1.36 1.17 2.27 5.92
KLA/ATP 1.51 1.64 1.35 1.78 1.34 1.20 2.96
Mpo
KLA  ATP  ATP+KLA
 NM_010824 myeloperoxidase (Mpo), nuclear gene encoding mitochondrial protein, mRNA [NM_010824] KLA 1.13 1.22 1.15 1.19 .97 .97 1.07
ATP .92 1.06 1.50 1.90 1.74 1.21 .86
KLA/ATP 1.20 1.36 1.48 1.94 2.16 1.84 .95
Myc
KLA  ATP  ATP+KLA
 NM_010849 myelocytomatosis oncogene (Myc), mRNA [NM_010849] KLA .38 .31 .45 .45 .49 .35 .33
ATP 1.05 1.09 1.72 4.41 1.28 .45 .76
KLA/ATP .37 .30 .44 1.23 .34 .17 .19
Mycn
KLA  ATP  ATP+KLA
 NM_008709 v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) (Mycn), mRNA [NM_008709] KLA .93 .93 .98 1.03 1.00 .96 .97
ATP 1.02 .99 1.01 1.00 1.00 .94 .97
KLA/ATP .98 .99 .96 .94 .99 1.02 .90
Ncor1
KLA  ATP  ATP+KLA
 NM_011308 nuclear receptor co-repressor 1 (Ncor1), mRNA [NM_011308] KLA .98 .90 .92 .97 1.05 1.04 1.11
ATP 1.20 1.14 1.03 1.12 .90 .73 1.15
KLA/ATP 1.04 1.06 1.00 .94 .84 .72 1.22
Nfkb1
KLA  ATP  ATP+KLA
 BC050841 nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] KLA 5.81 4.96 4.77 3.21 3.37 2.00 1.71
ATP 1.39 1.52 3.25 12.63 13.64 4.80 1.08
KLA/ATP 7.21 8.69 19.53 23.93 11.70 2.85 2.01
Nfkb1
KLA  ATP  ATP+KLA
 M57999 gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] KLA 8.55 7.87 7.35 6.13 3.51 1.85 1.38
ATP .98 .96 1.21 3.06 5.29 4.67 .69
KLA/ATP 7.32 7.20 8.71 10.82 5.55 2.77 1.54
Nfkbiz
KLA  ATP  ATP+KLA
 NM_030612 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta (Nfkbiz), mRNA [NM_030612] KLA 40.65 35.22 49.79 35.42 17.91 8.15 8.01
ATP 4.11 6.78 22.01 43.36 40.47 9.81 .97
KLA/ATP 40.40 38.84 55.70 49.53 27.03 11.18 10.28
Ngfr
KLA  ATP  ATP+KLA
 NM_033217 nerve growth factor receptor (TNFR superfamily, member 16) (Ngfr), mRNA [NM_033217] KLA 1.06 1.08 1.08 1.06 1.07 1.09 1.08
ATP .99 1.01 1.06 1.03 1.01 1.04 1.04
KLA/ATP 1.04 1.07 1.08 1.06 1.05 1.04 1.11
Nr4a3
KLA  ATP  ATP+KLA
 NM_015743 nuclear receptor subfamily 4, group A, member 3 (Nr4a3), mRNA [NM_015743] KLA 1.07 1.03 1.05 .96 1.04 1.03 1.01
ATP .99 1.06 1.28 1.47 1.23 1.04 1.05
KLA/ATP 1.01 1.04 1.18 1.33 1.19 1.05 1.02
Ntrk1
KLA  ATP  ATP+KLA
 NM_001033124 neurotrophic tyrosine kinase, receptor, type 1 (Ntrk1), mRNA [NM_001033124] KLA .95 .96 1.03 1.03 .95 1.01 1.02
ATP 1.04 .98 .98 1.07 .99 1.01 1.02
KLA/ATP .97 1.03 1.10 1.02 1.05 1.00 .97
Nupr1
KLA  ATP  ATP+KLA
 NM_019738 nuclear protein 1 (Nupr1), mRNA [NM_019738] KLA 7.75 8.76 8.21 9.50 12.14 12.94 10.48
ATP 1.08 1.14 1.27 1.76 3.34 6.56 6.44
KLA/ATP 7.84 8.71 10.22 11.80 14.29 16.70 22.56
Pax3
KLA  ATP  ATP+KLA
 NM_008781 paired box gene 3 (Pax3), mRNA [NM_008781] KLA 1.00 1.00 .99 1.00 1.02 1.00 1.01
ATP .99 1.03 1.02 1.00 1.01 1.00 1.05
KLA/ATP 1.00 .99 1.01 1.01 1.01 .98 1.00
Pax5
KLA  ATP  ATP+KLA
 NM_008782 paired box gene 5 (Pax5), mRNA [NM_008782] KLA .97 .99 .96 .98 1.02 .98 1.05
ATP .95 1.01 .99 1.05 .98 .99 1.05
KLA/ATP 1.04 .99 .98 1.00 1.02 1.01 1.01
Pax7
KLA  ATP  ATP+KLA
 NM_011039 paired box gene 7 (Pax7), mRNA [NM_011039] KLA 1.05 1.01 .99 .98 1.05 1.03 1.04
ATP 1.05 1.02 1.05 1.02 1.03 1.01 1.03
KLA/ATP 1.04 .96 1.00 1.10 1.01 1.00 1.03
Pax8
KLA  ATP  ATP+KLA
 AK032920 12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720473A10 product:paired box gene 8, full insert sequence [AK032920] KLA .93 .91 .92 .91 1.02 1.07 1.04
ATP .98 1.06 .98 .99 1.00 1.02 .94
KLA/ATP .92 .95 .97 1.03 .98 .91 .89
Pax8
KLA  ATP  ATP+KLA
 NM_011040 paired box gene 8 (Pax8), mRNA [NM_011040] KLA 1.06 .96 1.07 1.01 1.03 .99 1.03
ATP 1.10 .97 1.01 1.04 .97 1.00 1.00
KLA/ATP 1.09 1.06 1.03 .94 .92 .92 .99
Pbx1
KLA  ATP  ATP+KLA
 NM_183355 pre B-cell leukemia transcription factor 1 (Pbx1), transcript variant a, mRNA [NM_183355] KLA 1.05 1.12 1.16 1.07 1.01 .87 .85
ATP 1.03 1.08 1.00 1.17 .95 .95 1.12
KLA/ATP 1.10 1.11 .99 1.27 1.42 1.88 1.53
Pbx3
KLA  ATP  ATP+KLA
 AK052017 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230035L23 product:unclassifiable, full insert sequence. [AK052017] KLA .96 1.00 .95 .97 .96 1.07 1.03
ATP 1.05 .91 1.00 1.00 1.04 1.09 .98
KLA/ATP .98 .94 .98 .95 1.06 1.05 1.12
Pbx3
KLA  ATP  ATP+KLA
 NM_016768 pre B-cell leukemia transcription factor 3 (Pbx3), mRNA [NM_016768] KLA .57 .56 .56 .60 .51 .69 1.00
ATP .94 .96 1.22 1.37 1.19 1.32 .74
KLA/ATP .58 .57 .68 .72 .80 .94 .90
Pdgfa
KLA  ATP  ATP+KLA
 NM_008808 platelet derived growth factor, alpha (Pdgfa), mRNA [NM_008808] KLA .63 .56 .42 .34 .31 .33 .52
ATP .89 .80 .69 1.23 5.97 3.99 2.73
KLA/ATP .64 .53 .43 .77 3.48 3.78 2.37
Pdgfb
KLA  ATP  ATP+KLA
 NM_011057 platelet derived growth factor, B polypeptide (Pdgfb), mRNA [NM_011057] KLA .45 .43 .38 .46 .69 .48 .58
ATP .94 .95 .66 .74 .67 .77 1.06
KLA/ATP .43 .43 .37 .39 .52 .55 1.64
Per2
KLA  ATP  ATP+KLA
 NM_011066 period homolog 2 (Drosophila) (Per2), mRNA [NM_011066] KLA .81 .79 .76 .78 1.01 1.24 1.11
ATP 1.03 1.03 1.07 1.09 .98 1.23 .98
KLA/ATP .79 .75 .81 .81 1.03 1.15 .81
Pftk1
KLA  ATP  ATP+KLA
 AK051283 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130028L24 product:PFTAIRE protein kinase 1, full insert sequence. [AK051283] KLA 1.24 1.13 1.01 1.27 1.25 1.15 1.04
ATP 1.14 1.06 1.01 1.05 .94 .97 1.04
KLA/ATP 1.17 1.25 1.59 1.22 1.23 .94 1.19
Pftk1
KLA  ATP  ATP+KLA
 NM_011074 PFTAIRE protein kinase 1 (Pftk1), mRNA [NM_011074] KLA .75 .68 .69 .62 .74 .73 .80
ATP 1.09 1.06 .81 .74 .47 .29 .61
KLA/ATP .80 .66 .49 .50 .44 .32 .62
Plat
KLA  ATP  ATP+KLA
 AK053476 0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130020K19 product:plasminogen activator, tissue, full insert sequence [AK053476] KLA 1.06 1.02 1.06 .99 1.11 .97 1.03
ATP .93 1.10 1.82 4.69 1.17 1.06 1.10
KLA/ATP 1.02 .99 1.38 1.87 1.09 1.03 1.01
Plat
KLA  ATP  ATP+KLA
 NM_008872 plasminogen activator, tissue (Plat), mRNA [NM_008872] KLA 3.87 3.94 2.80 2.09 1.92 1.41 1.20
ATP 1.08 1.07 2.42 10.85 8.51 3.53 1.28
KLA/ATP 3.87 4.26 3.93 7.51 5.17 4.48 1.90
Plau
KLA  ATP  ATP+KLA
 NM_008873 plasminogen activator, urokinase (Plau), mRNA [NM_008873] KLA .28 .27 .22 .23 .19 .25 .27
ATP .99 1.19 1.63 2.44 1.52 .49 1.12
KLA/ATP .26 .29 .32 .40 .35 .32 .48
Pml
KLA  ATP  ATP+KLA
 NM_008884 promyelocytic leukemia (Pml), transcript variant 1, mRNA [NM_008884] KLA 5.73 6.01 7.28 6.76 5.85 5.36 2.28
ATP 1.07 1.10 .92 .89 .97 3.78 2.67
KLA/ATP 6.48 6.51 6.81 8.78 6.61 7.57 6.55
Pparg
KLA  ATP  ATP+KLA
 NM_011146 peroxisome proliferator activated receptor gamma (Pparg), mRNA [NM_011146] KLA .32 .28 .31 .45 .38 .35 .49
ATP .96 1.01 1.28 1.65 1.83 .57 .77
KLA/ATP .30 .29 .36 .53 1.23 .72 .55
Prcc
KLA  ATP  ATP+KLA
 NM_033573 papillary renal cell carcinoma (translocation-associated) (Prcc), mRNA [NM_033573] KLA .92 .86 .97 1.12 1.05 1.08 .93
ATP .99 1.01 1.27 1.27 1.02 1.87 1.01
KLA/ATP .88 .89 1.19 1.33 1.24 1.80 1.25
Prom1
KLA  ATP  ATP+KLA
 NM_008935 prominin 1 (Prom1), mRNA [NM_008935] KLA 1.01 .99 1.06 1.01 1.03 .99 1.02
ATP 1.06 .98 1.01 .97 .93 1.00 .99
KLA/ATP 1.05 1.02 1.01 .98 1.01 1.06 1.08
Ptcra
KLA  ATP  ATP+KLA
 NM_011195 pre T-cell antigen receptor alpha (Ptcra), mRNA [NM_011195] KLA .99 .92 .98 .97 .94 1.01 .92
ATP .98 1.00 1.01 .97 1.01 .97 1.00
KLA/ATP .99 1.04 1.06 .93 1.00 .91 1.06
Ptk2
KLA  ATP  ATP+KLA
 NM_007982 PTK2 protein tyrosine kinase 2 (Ptk2), mRNA [NM_007982] KLA .99 .99 1.02 1.04 1.09 1.22 1.57
ATP 1.04 1.09 .95 .98 .67 .96 .87
KLA/ATP .99 1.03 .87 .93 .81 1.16 1.04
Rara
KLA  ATP  ATP+KLA
 NM_009024 retinoic acid receptor, alpha (Rara), mRNA [NM_009024] KLA .83 .88 .84 .91 .94 .95 .88
ATP 1.00 1.12 1.01 .97 1.19 .93 1.20
KLA/ATP .93 .90 .88 .91 .95 .95 .91
Rel
KLA  ATP  ATP+KLA
 NM_009044 reticuloendotheliosis oncogene (Rel), mRNA [NM_009044] KLA 6.20 5.99 6.38 3.19 1.97 1.61 1.46
ATP 1.09 1.31 2.22 2.64 3.14 2.16 1.56
KLA/ATP 6.79 7.15 6.97 5.37 3.14 2.05 2.16
Rela
KLA  ATP  ATP+KLA
 NM_009045 v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] KLA 2.05 2.05 2.07 1.75 1.83 1.58 1.33
ATP 1.03 1.08 1.10 1.44 1.61 2.48 1.05
KLA/ATP 2.17 2.27 2.05 2.47 1.93 2.35 2.02
Runx1
KLA  ATP  ATP+KLA
 NM_001111023 runt related transcription factor 1 (Runx1), transcript variant 3, mRNA [NM_001111023] KLA 1.14 1.21 1.40 1.59 1.67 1.51 1.33
ATP 1.02 1.33 1.55 2.35 2.05 1.69 1.70
KLA/ATP 1.18 1.43 1.51 2.75 2.38 1.88 2.62
Runx1
KLA  ATP  ATP+KLA
 NM_009821 runt related transcription factor 1 (Runx1), transcript variant 4, mRNA [NM_009821] KLA .74 .75 .93 1.11 1.15 .87 .89
ATP 1.23 1.19 1.06 1.78 1.35 .47 .76
KLA/ATP .77 .76 .74 1.41 1.55 .48 .61
Runx1t1
KLA  ATP  ATP+KLA
 NM_009822 runt-related transcription factor 1; translocated to, 1 (cyclin D-related) (Runx1t1), transcript variant 3, mRNA [NM_009822] KLA .99 .95 .96 1.01 1.05 1.01 .97
ATP 1.05 1.05 1.02 1.02 1.02 1.05 1.06
KLA/ATP 1.01 1.00 .97 1.01 .99 1.01 1.10
Runx2
KLA  ATP  ATP+KLA
 D14636 mRNA for PEBP2a1 protein, complete cds [D14636] KLA .82 .79 .75 .75 .67 .72 .87
ATP 1.04 1.08 1.40 1.60 3.96 6.15 1.74
KLA/ATP .79 .82 .99 1.10 2.27 2.71 1.98
Runx2
KLA  ATP  ATP+KLA
 NM_009820 runt related transcription factor 2 (Runx2), mRNA [NM_009820] KLA 1.01 .98 .96 1.01 1.04 .96 .95
ATP 1.00 1.06 1.06 1.00 1.26 1.59 1.23
KLA/ATP .99 .98 1.03 1.04 1.05 1.18 1.27
Rxra
KLA  ATP  ATP+KLA
 NM_011305 retinoid X receptor alpha (Rxra), mRNA [NM_011305] KLA .53 .55 .50 .52 .54 .85 1.09
ATP .95 1.00 1.18 1.00 .82 1.20 1.65
KLA/ATP .57 .55 .58 .55 .67 1.07 1.57
Rxrb
KLA  ATP  ATP+KLA
 NM_011306 retinoid X receptor beta (Rxrb), mRNA [NM_011306] KLA .71 .75 .75 .76 .83 .81 .89
ATP 1.04 1.13 .94 1.20 1.13 .81 .75
KLA/ATP .80 .86 .72 .85 .83 .93 .92
Rxrg
KLA  ATP  ATP+KLA
 NM_009107 retinoid X receptor gamma (Rxrg), mRNA [NM_009107] KLA .98 1.07 1.07 1.00 1.00 1.00 1.07
ATP 1.02 1.03 1.06 1.06 1.11 1.01 .99
KLA/ATP .95 .97 1.05 1.05 1.09 .98 1.06
Sfpi1
KLA  ATP  ATP+KLA
 NM_011355 SFFV proviral integration 1 (Sfpi1), mRNA [NM_011355] KLA 2.54 2.77 2.96 2.31 3.22 2.44 2.29
ATP 1.17 1.55 .79 1.96 1.49 1.23 1.66
KLA/ATP 3.35 3.40 1.30 3.78 1.70 1.80 3.18
Sin3a
KLA  ATP  ATP+KLA
 NM_011378 transcriptional regulator, SIN3A (yeast) (Sin3a), transcript variant 1, mRNA [NM_011378] KLA .55 .51 .51 .75 .98 1.09 .90
ATP 1.10 .93 .78 .89 1.51 1.35 1.01
KLA/ATP .52 .48 .53 .51 1.40 1.26 1.25
Six1
KLA  ATP  ATP+KLA
 NM_009189 sine oculis-related homeobox 1 homolog (Drosophila) (Six1), mRNA [NM_009189] KLA 1.65 1.73 1.55 1.41 1.19 1.13 1.12
ATP 1.02 1.05 1.10 1.07 1.23 1.75 1.05
KLA/ATP 1.60 1.88 1.70 1.61 1.21 1.28 1.43
Six1
KLA  ATP  ATP+KLA
 X80339 gb|M.musculus Six1 mRNA. [X80339] KLA 1.18 1.25 1.11 1.09 .95 1.07 1.10
ATP .95 .98 1.06 1.12 1.16 1.41 1.02
KLA/ATP 1.23 1.31 1.19 1.23 1.10 1.12 1.05
Six4
KLA  ATP  ATP+KLA
 NM_011382 sine oculis-related homeobox 4 homolog (Drosophila) (Six4), mRNA [NM_011382] KLA 1.02 1.05 .92 1.03 .95 1.01 1.03
ATP 1.05 .98 .97 1.00 1.01 1.00 1.05
KLA/ATP 1.02 1.05 1.05 .96 .98 1.03 .97
Slc45a3
KLA  ATP  ATP+KLA
 NM_145977 solute carrier family 45, member 3 (Slc45a3), mRNA [NM_145977] KLA 1.00 1.09 1.09 .97 .94 .86 .76
ATP 1.00 1.07 1.10 1.09 2.19 1.44 1.79
KLA/ATP 1.17 1.18 1.13 1.19 2.11 1.56 .92
Smad1
KLA  ATP  ATP+KLA
 NM_008539 MAD homolog 1 (Drosophila) (Smad1), mRNA [NM_008539] KLA .54 .60 .74 .93 1.36 1.54 1.27
ATP .99 1.02 .81 .87 1.26 .93 .84
KLA/ATP .57 .55 .54 .63 1.04 .97 .88
Sp1
KLA  ATP  ATP+KLA
 NM_013672 trans-acting transcription factor 1 (Sp1), mRNA [NM_013672] KLA .81 .75 .67 .79 .89 1.00 .84
ATP .96 1.01 1.13 .93 1.30 1.51 .84
KLA/ATP .73 .74 .81 .66 1.38 1.34 1.20
Spint1
KLA  ATP  ATP+KLA
 NM_016907 serine protease inhibitor, Kunitz type 1 (Spint1), mRNA [NM_016907] KLA .98 .97 .88 .95 .96 1.05 1.08
ATP .99 .99 1.00 1.07 .99 2.05 10.84
KLA/ATP .97 .92 1.06 .95 1.00 1.86 3.77
Ss18
KLA  ATP  ATP+KLA
 NM_009280 synovial sarcoma translocation, Chromosome 18 (Ss18), mRNA [NM_009280] KLA .66 .66 .56 .49 .35 .45 .62
ATP .93 .96 1.09 .72 .66 .72 .61
KLA/ATP .60 .62 .67 .51 .51 .50 .33
Supt3h
KLA  ATP  ATP+KLA
 NM_178652 suppressor of Ty 3 homolog (S. cerevisiae) (Supt3h), mRNA [NM_178652] KLA .89 .95 .83 .76 .62 .66 1.03
ATP 1.02 1.08 .99 1.15 1.03 .93 1.06
KLA/ATP 1.02 .92 .90 1.01 .81 .74 .89
Taf15
KLA  ATP  ATP+KLA
 NM_027427 TAF15 RNA polymerase II, TATA box binding protein (TBP)-associated factor (Taf15), mRNA [NM_027427] KLA 1.51 1.56 1.95 1.33 1.25 1.30 1.28
ATP 1.13 1.16 1.56 1.05 2.10 1.43 1.03
KLA/ATP 1.60 1.68 2.71 1.79 1.63 1.16 1.08
Tcfe2a
KLA  ATP  ATP+KLA
 NM_011548 transcription factor E2a (Tcfe2a), mRNA [NM_011548] KLA .72 .66 .57 .57 .65 .73 .75
ATP 1.11 1.26 .97 1.15 .69 .71 .84
KLA/ATP .61 .70 .58 .69 .50 .62 .66
Tcfe3
KLA  ATP  ATP+KLA
 NM_001105196 transcription factor E3 (Tcfe3), transcript variant 2, mRNA [NM_001105196] KLA 1.07 .99 1.06 1.13 1.28 1.42 1.44
ATP 1.09 1.26 .94 1.07 .80 1.13 1.15
KLA/ATP .99 1.06 .91 .97 .80 1.11 1.36
Tcfe3
KLA  ATP  ATP+KLA
 NM_172472 transcription factor E3 (Tcfe3), transcript variant 1, mRNA [NM_172472] KLA .86 .89 1.05 1.15 1.66 1.53 1.52
ATP 1.03 1.27 .84 1.04 .89 1.34 1.17
KLA/ATP .99 .96 .69 .88 .78 1.34 1.70
Tgfbr2
KLA  ATP  ATP+KLA
 AK090393 10 days pregnant adult female ovary and uterus cDNA, RIKEN full-length enriched library, clone:G630098D03 product:transforming growth factor, beta receptor II, full insert sequence. [AK090393] KLA .98 .89 1.00 .96 .94 1.00 .92
ATP .99 .99 .90 .94 .93 .96 1.02
KLA/ATP .92 .96 .98 .98 .98 .95 1.01
Tgfbr2
KLA  ATP  ATP+KLA
 NM_009371 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 1, mRNA [NM_009371] KLA .55 .50 .58 .50 .52 .55 .44
ATP .98 .75 .50 .32 .41 .29 .50
KLA/ATP .59 .45 .32 .23 .31 .27 .25
Tgfbr2
KLA  ATP  ATP+KLA
 NM_029575 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 2, mRNA [NM_029575] KLA .95 .93 .99 .95 .88 1.02 .82
ATP .87 .93 .84 .84 .74 .72 1.00
KLA/ATP .89 .85 .83 .85 .76 .80 .79
Tlx1
KLA  ATP  ATP+KLA
 NM_021901 T-cell leukemia, homeobox 1 (Tlx1), mRNA [NM_021901] KLA .98 .97 1.04 .97 .99 .98 1.00
ATP .99 .97 .96 .95 .95 .99 1.00
KLA/ATP 1.00 1.09 1.00 .97 .97 .98 .99
Tlx3
KLA  ATP  ATP+KLA
 NM_019916 T-cell leukemia, homeobox 3 (Tlx3), mRNA [NM_019916] KLA 1.02 1.03 1.09 1.02 .94 .97 .98
ATP 1.01 1.01 1.06 1.00 .98 1.01 1.00
KLA/ATP .99 1.01 1.02 1.04 .90 .93 .95
Tmprss2
KLA  ATP  ATP+KLA
 NM_015775 transmembrane protease, serine 2 (Tmprss2), mRNA [NM_015775] KLA 1.03 .99 1.01 1.03 1.01 1.04 1.01
ATP 1.03 1.01 .99 1.02 1.00 1.00 .99
KLA/ATP 1.02 1.01 1.07 1.02 1.02 1.00 .99
Traf1
KLA  ATP  ATP+KLA
 NM_009421 Tnf receptor-associated factor 1 (Traf1), mRNA [NM_009421] KLA 44.86 39.03 38.11 34.21 36.49 19.69 14.75
ATP 1.14 1.04 1.98 8.16 16.79 30.81 6.36
KLA/ATP 46.20 45.67 45.63 38.00 27.26 31.47 63.83
Trp53
KLA  ATP  ATP+KLA
 NM_011640 transformation related protein 53 (Trp53), mRNA [NM_011640] KLA 1.25 1.37 1.11 .86 .72 .71 .95
ATP 1.15 1.32 .90 1.85 1.26 .68 .70
KLA/ATP 1.66 1.49 .80 1.76 .81 .65 .74
Tspan7
KLA  ATP  ATP+KLA
 NM_019634 tetraspanin 7 (Tspan7), mRNA [NM_019634] KLA 1.03 1.00 1.07 1.01 1.01 .97 .88
ATP 1.00 1.00 1.17 1.11 1.18 1.19 1.46
KLA/ATP 1.06 1.13 1.11 1.18 1.09 1.02 1.25
Utx
KLA  ATP  ATP+KLA
 AK080370 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630079C23 product:ubiquitously transcribed tetratricopeptide repeat gene, X chromosome, full insert sequence. [AK080370] KLA 1.00 1.00 .98 .98 .99 .95 1.00
ATP 1.02 1.00 .97 .92 1.01 .97 1.06
KLA/ATP 1.04 1.10 .95 .99 .95 1.02 .94
Utx
KLA  ATP  ATP+KLA
 NM_009483 ubiquitously transcribed tetratricopeptide repeat gene, X chromosome (Utx), mRNA [NM_009483] KLA 1.07 1.12 1.01 1.14 1.17 1.38 1.53
ATP 1.13 1.25 .86 1.20 .97 .91 1.27
KLA/ATP 1.12 1.07 .70 1.10 .87 1.24 1.84
Uty
KLA  ATP  ATP+KLA
 AK043154 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730061A15 product:ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome, full insert sequence. [AK043154] KLA 1.01 1.04 1.00 .98 1.03 .95 .98
ATP 1.02 1.02 .94 1.02 1.03 1.00 .98
KLA/ATP 1.08 1.08 1.00 1.01 1.03 .94 .97
Uty
KLA  ATP  ATP+KLA
 NM_009484 ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome (Uty), mRNA [NM_009484] KLA 1.01 .95 .84 1.00 1.01 1.01 1.02
ATP 1.02 1.17 1.10 1.06 .69 .91 .80
KLA/ATP .94 1.01 .95 .96 .73 .88 .90
Whsc1
KLA  ATP  ATP+KLA
 AK079112 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430010A17 product:PUTATIVE WHSC1 PROTEIN homolog [Homo sapiens], full insert sequence. [AK079112] KLA .61 .55 .58 .60 .73 .85 .81
ATP 1.07 1.13 .90 .71 .47 .44 1.44
KLA/ATP .58 .54 .53 .49 .50 .43 .70
Whsc1
KLA  ATP  ATP+KLA
 NM_001081102 Wolf-Hirschhorn syndrome candidate 1 (human) (Whsc1), mRNA [NM_001081102] KLA .36 .37 .51 .51 .61 .85 .52
ATP 1.01 1.07 1.07 1.05 .67 .51 1.34
KLA/ATP .42 .40 .46 .43 .49 .64 1.06
Wnt16
KLA  ATP  ATP+KLA
 NM_053116 wingless-related MMTV integration site 16 (Wnt16), mRNA [NM_053116] KLA 1.00 1.02 .97 1.02 .96 1.02 1.05
ATP 1.01 1.00 .97 .98 .97 .95 1.02
KLA/ATP .96 1.01 .98 1.03 .99 1.00 .97
Wt1
KLA  ATP  ATP+KLA
 NM_144783 Wilms tumor homolog (Wt1), mRNA [NM_144783] KLA 1.01 1.00 1.01 .98 1.00 1.00 1.01
ATP 1.00 .99 1.00 1.02 1.00 1.02 1.01
KLA/ATP 1.01 1.02 1.01 .99 1.01 1.00 1.02
Zbtb17
KLA  ATP  ATP+KLA
 NM_009541 zinc finger and BTB domain containing 17 (Zbtb17), mRNA [NM_009541] KLA .78 .82 .90 .76 .87 .84 1.04
ATP 1.01 1.05 .94 1.58 2.04 1.29 1.21
KLA/ATP .86 .81 .77 .96 1.44 1.28 1.44
Zeb1
KLA  ATP  ATP+KLA
 NM_011546 zinc finger E-box binding homeobox 1 (Zeb1), mRNA [NM_011546] KLA 7.46 7.12 7.54 6.66 5.19 5.70 3.11
ATP .97 .90 1.13 1.19 1.45 2.65 1.96
KLA/ATP 7.16 7.81 7.11 6.11 3.92 3.53 5.86